Form 4: Evolent Health CEO Seth Blackley's Stock Transactions

Evolent Health CEO Seth Blackley reported transactions involving restricted stock units and common stock, including a significant grant of RSUs.

Summary

• Seth Blackley, Chief Executive Officer and Director of Evolent Health, Inc. (EVH), reported transactions on July 1, 2026.
• He acquired 446,102 shares of Class A Common Stock as part of an RSU award, valued at $0, bringing his total beneficial ownership to 1,283,064 shares.
• Additionally, 10,297 shares of Class A Common Stock were disposed of to cover tax withholding obligations upon vesting of RSUs, with a value of $5.74 per share, reducing his directly held shares to 1,272,767.
• The RSU award was granted under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, following shareholder approval for additional shares on June 4, 2026.
• The RSUs vest in tranches: 34% on July 1, 2027, and 33% on July 1, 2028, and July 1, 2029.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily detailing routine executive compensation and stock transactions rather than significant financial performance or strategic shifts.

Positives

• Significant grant of restricted stock units (446,102 shares) to the CEO, indicating continued incentive alignment.
• Shareholder approval for additional shares under the incentive plan on June 4, 2026, supports future equity awards.
• The CEO's beneficial ownership remains substantial at 1,283,064 shares after the transactions.

Negatives

• Disposal of 10,297 shares to cover tax withholding obligations suggests a cash outflow or reduction in net shares held by the executive.

Risks

• Vesting schedule for RSUs extends over several years (2027-2029), meaning the full benefit is not immediate.
• The value of the RSU award is contingent on the future stock price performance of Evolent Health, Inc.

Future Outlook

The vesting schedule for the granted RSUs extends through July 1, 2029, indicating a long-term incentive structure for the CEO.

Industry Context

StockSavvy.ai notes that the granting of RSUs to key executives, as seen in this Form 4 filing by Evolent Health's CEO, is a common practice in the healthcare technology and managed care sectors to attract, retain, and incentivize leadership aligned with long-term company performance.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant and subsequent vesting align executive interests with long-term shareholder value, but also dilute ownership slightly over time.
• Employees: The incentive plan update suggests continued focus on equity-based compensation, potentially benefiting other employees as well.
• Management: The CEO receives a significant equity award, reinforcing their commitment and incentivizing performance.

Next Steps

• Vesting of restricted stock units on July 1, 2027, July 1, 2028, and July 1, 2029.

Key Dates

Keywords

Evolent Health, EVH, Form 4, Seth Blackley, Restricted Stock Units, RSU, Stock Transaction, Insider Trading, Executive Compensation, Class A Common Stock, Beneficial Ownership